Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin

Breast Cancer Research and Treatment

Volumn 50, Issue 2, 1998, Pages 167-174

  Nieto, Yago ^a,b   Martín, Miguel ^a   Alonso, José Luis ^a   Casado, Antonio ^a   Ayala, Francisco ^a   López Martín, José Antonio ^a   Rodríguez Lescure, Alvaro ^a   Díaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

5 Fluorouracil; Anthracycline resistant breast cancer; Biochemical modulation; Continuous infusion; Doxorubicin resistant breast cancer; Metastatic breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; PUSTULOSIS PALMOPLANTARIS; SOFT TISSUE; THROMBOCYTOPENIA; VISCERA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MIDDLE AGED; PALLIATIVE CARE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031664997     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006062018355     Document Type: Article

References (29)

1. O'Connell MJ: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63: 1026-1030, 1989
2. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890-899, 1989
3. Loprinzi CL, Ingle JN, Schaid DJ, Buckner JC, Edmonson JH, Allegra CJ: 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. Am J Clin Oncol 14: 30-32, 1991
4. Doroshow JH, Leong L, Margolin KA, Odujinrin O, Newman E: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7: 439-444, 1989
5. Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Somlo G, Raschko J, Pereira C, Yonemoto L, Ahn C: Effective initial therapy of advanced breast cancer with fluorouracil and high-dose continuous infusion calcium leucovorin. J Clin Oncol 10: 1278-1283, 1992
6. Lokich J, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 7: 425-432, 1989
7. Weinerman B, Shah A, Field A et al.: A randomized trial of continuous systemic infusion versus bolus therapy with 5-fluorouracil in metastatic measurable colorectal cancer. Proc Am Soc Clin Oncol 7: 425-432, 1990
8. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. J Clin Oncol 13: 1303-1311, 1995
9. Huan S, Pazdur R, Singhakowinta A, Samal B, Vaitkevicius VK: Low-dose continuous infusion 5-fluorouracil. Cancer 63: 419-422, 1989
10. Jabboury K, Holmes FA, Hortobagyi G: 5′-fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64: 793-797, 1989
11. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S, et al.: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429, 1995
12. Romanini A, Lin JT, Niedzwiecki D, Bunni M, Priest PG, Bertino JR: Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 51: 789-793, 1991
13. Moran RG, Scanlon KL: Schedule dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 51: 4618-4623, 1991
14. Leichman CG, Leichman L, Spears CP, Rosen PJ, Jeffers S, Groshen S: Phase II study of prolonged infusion 5-fluorouracil with weekly leucovorin in disseminated colorectal cancer. J Natl Cancer Inst 85: 41-44, 1993
15. Aranda E, Cervantes A, Dorta J, Blanco E, Fernández-Martos C, Cruz-Hernández JJ, Carrato A, González-Mancha R, García-Conde J, Díaz-Rubio E: A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. Cancer 76: 559-563, 1995
16. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
17. Martín M, Díaz-Rubio E, Casado A, López JA, Rodríguez A, Ayala F, Nieto Y: FlexiFAC: A modified schedule for breast cancer. Proc Am Soc Clin Oncol 13: 107 (abstr. 229). 1994
18. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Bhandari A, Valero V, Buzdar AU: A unified definition of clinical anthracycline resistant breast cancer. Proc Am Soc Clin Oncol 16: 146a (abstr. 512), 1997
19. Wilke H, Klaassen U, Achterrath W, Losch M, Vanhoefer U, Hayungs J, Harstrick A, Stahl AM, Eberhardt W, Becher R, Seeber S: Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 7: 55-58, 1996
20. Valero V, Holmes F, Walters R, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894, 1995
21. Ravdin P, Burris H III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995
22. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 12: 1621-1629, 1994
23. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Norton L: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995
24. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte O, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B: Randomized trial of two doses of paclitaxel in metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996
25. Gianni L, Capri G, Munzone E, Straneo M: Paclitaxel (taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 21 (5 Suppl 8): 29-33, 1994
26. Vermorken JB, Ten Bokkel Huinink WW, Mandjes IA, Postma TJ, Huizing MT, Heimans JJ, Beijnen JH, Bierhorst F, Winograd B, Pinedo HM: High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Semin Oncol 22 (4 Suppl 8): 16-22, 1995
27. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, Demaille A: Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 423-426, 1994
28. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567-2574, 1995
29. Lokich JJ, Moore CL, Anderson NR: Comparison of costs for infusion versus bolus chemotherapy administration: Analysis of five chemotherapy regimens in three common tumors. Part one. Model projections for cost based on charges. Cancer 78: 294-299, 1996